Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SEA Vision Launches HarleNir | Contract Pharma

What are you searching for?

Sign in
Breaking News

SEA Vision Launches HarleNir

Near Infrared Hyperspectral vision system can inspect an entire batch on the manufacturing line in a fully automated fashion

By: Betsy Louda

, Contract Pharma

SEA Vision has launched its Near Infrared Hyperspectral vision (NIR) system, HarleNir.
 
Based on its Harlequin blister control system, HarleNIR is a new generation of blister inspection technology that goes beyond visible inspection to provide a chemical analysis of drug products. HarleNIR can inspect an entire batch on the manufacturing line in a fully automated fashion, removing human error and speeding up batch release times. Even if a product appears visually sound, errors in the API can now be identified.  
 
Paolo Landriani, business development manager at SEA Vision, said, “We have been designing inspection system for quality control for more than 20 years and this latest technology allows us to take inspection processes to the next level. Through integrated imaging technology, HarleNIR can distinguish products directly from their active ingredients and perform a chemical analysis to identify compounds with different active principle, different dosage or measure the active ingredient uniformity distribution inside products.” 

 
 
 
 
 
 
 
 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics